#1 Clinical Trials Search in Europe

Corifollitropin Alfa

Corifollitropin alfa, also known by the brand name Elonva, is a long-acting follicle-stimulating hormone (FSH) used in fertility treatments. This article explores various clinical trials investigating the use of corifollitropin alfa in controlled ovarian stimulation for in vitro fertilization (IVF) and other assisted reproductive technologies. These studies aim to optimize treatment protocols, improve outcomes, and enhance patient experiences in fertility treatments.

Table of Contents

What is Corifollitropin Alfa?

Corifollitropin alfa, also known by its brand name Elonva, is a medication used in fertility treatments[1]. It belongs to a class of drugs called gonadotropins, which are hormones that stimulate the ovaries or testes. Corifollitropin alfa is a long-acting form of follicle-stimulating hormone (FSH), designed to provide sustained stimulation of the ovaries for seven days with a single injection[2].

How Does It Work?

Corifollitropin alfa works by stimulating the ovaries to produce multiple follicles (small sacs containing eggs) during a single menstrual cycle. This process is known as controlled ovarian stimulation. By producing multiple follicles, the chances of obtaining viable eggs for in vitro fertilization (IVF) procedures are increased[1].

Unlike traditional FSH medications that require daily injections, corifollitropin alfa provides a sustained effect for an entire week with just one injection. This can significantly reduce the number of injections needed during fertility treatment[2].

Conditions Treated

Corifollitropin alfa is primarily used in the treatment of:

  • Female Infertility: It is used as part of assisted reproductive technology (ART) programs, particularly for in vitro fertilization (IVF)[2].
  • Polycystic Ovary Syndrome (PCOS): Some studies have explored its use in women with PCOS undergoing IVF treatment[1].
  • Male Hypogonadotropic Hypogonadism (HH): In combination with human chorionic gonadotropin (hCG), it has been studied for inducing testicular growth and sperm production in men with this condition[10].

Administration

Corifollitropin alfa is typically administered as follows:

  • Single Injection: A single subcutaneous (under the skin) injection is given at the start of the ovarian stimulation cycle[2].
  • Dosage: The dose is usually based on body weight. Women weighing 60 kg or less typically receive 100 μg, while those weighing more than 60 kg receive 150 μg[1].
  • Timing: The injection is usually given on day 2 or 3 of the menstrual cycle, although some studies have explored starting on day 4 or even in the luteal phase (second half) of the cycle[3][4][9].
  • Follow-up Treatment: After 7 days, if needed, daily injections of recombinant FSH may be given until the final day of stimulation[1].

Effectiveness

Studies have shown that corifollitropin alfa is effective in stimulating multiple follicle development. Its effectiveness has been compared to daily recombinant FSH injections in various patient groups:

  • Normal Responders: In women expected to have a normal ovarian response, corifollitropin alfa has shown similar effectiveness to daily FSH injections[5].
  • Poor Responders: Some studies have investigated its use in women who typically have a poor response to ovarian stimulation[2].
  • High Responders: Its use has also been studied in women expected to have a high ovarian response[5].
The primary measure of effectiveness is often the number of oocytes (eggs) retrieved after stimulation[5].

Side Effects

Like all medications, corifollitropin alfa can cause side effects. The most significant potential side effect is Ovarian Hyperstimulation Syndrome (OHSS), a condition where the ovaries become swollen and painful. Symptoms of OHSS can include abdominal pain, bloating, nausea, and in severe cases, shortness of breath[1].

Other potential side effects may include:

  • Pelvic pain
  • Headache
  • Mood swings
  • Nausea
  • Tiredness
  • Breast pain[2]

Special Considerations

Several important points should be considered when using corifollitropin alfa:

  • Monitoring: Regular monitoring of ovarian response through ultrasound and blood tests is crucial during treatment[1].
  • Combination with Other Medications: Corifollitropin alfa is often used in combination with other fertility medications, such as GnRH antagonists, to prevent premature ovulation[1].
  • Embryo Cryopreservation: In some cases, especially for patients at high risk of OHSS, all embryos may be frozen (cryopreserved) and transferred in a subsequent cycle[1].
  • Patient Satisfaction: Some studies have suggested that patients may prefer corifollitropin alfa due to the reduced number of injections required[5].
  • Ongoing Research: Studies are ongoing to further understand the optimal use of corifollitropin alfa in different patient populations and treatment protocols[6].

Aspect Details
Primary Use Controlled ovarian stimulation for IVF and other assisted reproductive technologies
Administration Single injection, sustaining follicle development for up to 7 days
Key Benefits Reduced injection burden, sustained follicle development, potential for improved treatment scheduling
Patient Populations Studied Expected normal responders, poor responders, high responders, PCOS patients
Areas of Investigation Optimal timing of administration, comparison with daily FSH, efficacy in different patient groups, impact on embryo development and pregnancy rates
Safety Considerations Risk of OHSS, especially in high responders; strategies to minimize risk being studied
Outcome Measures Number of oocytes retrieved, embryo quality, pregnancy rates, patient satisfaction, pharmacokinetics

FAQ

  • What is corifollitropin alfa? Corifollitropin alfa is a long-acting follicle-stimulating hormone (FSH) used in fertility treatments. It is designed to stimulate follicle development in the ovaries for a sustained period, typically up to 7 days, with a single injection.
  • How does corifollitropin alfa differ from daily FSH injections? Corifollitropin alfa is administered as a single injection that sustains follicle development for up to 7 days, whereas traditional FSH treatments require daily injections. This can potentially reduce the injection burden for patients undergoing fertility treatments.
  • What are some potential benefits of using corifollitropin alfa? Potential benefits include reduced injection burden for patients, sustained follicle development, and potentially improved scheduling flexibility for fertility treatments. Some studies also investigate its use in different patient populations, such as those with polycystic ovary syndrome (PCOS) or poor ovarian response.
  • Are there any risks associated with corifollitropin alfa? As with any fertility medication, there are potential risks. One concern is the risk of ovarian hyperstimulation syndrome (OHSS), especially in high-responder patients. Clinical trials are investigating protocols to minimize this risk, such as using GnRH agonist triggering and freezing all embryos in high-risk cases.
  • How is corifollitropin alfa being studied in clinical trials? Clinical trials are investigating various aspects of corifollitropin alfa use, including optimal timing of administration, its effectiveness in different patient populations, comparison with daily FSH injections, and its impact on embryo development and pregnancy rates. Some studies are also looking at patient satisfaction and the pharmacokinetics of the drug.

Ongoing Clinical Trials on Corifollitropin Alfa

  • Study on Corifollitropin Alfa and Follitropin Beta for Women with Infertility Undergoing Ovarian Stimulation with Medroxyprogesterone Acetate

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing Corifollitropin Alfa and Modified Natural Cycles for Women with Subfertility and Low Ovarian Response

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study Comparing Corifollitropin Alfa and Progestin Primed Ovarian Stimulation for Women with Subfertility Undergoing Elective Fertility Preservation or Genetic Testing

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study on the Effects of Follitropin Beta and Corifollitropin Alfa for Patients with Subfertility Undergoing ICSI Treatment

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study on Infertility: Comparing Corifollitropin Alfa and Follitropin Beta for Women Undergoing Elective Fertility Preservation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Corifollitropin alfa: A long-acting recombinant follicle-stimulating hormone (FSH) used in fertility treatments to stimulate follicle development in the ovaries for up to 7 days with a single injection.
  • Controlled Ovarian Stimulation (COS): A process in which fertility medications are used to stimulate the ovaries to produce multiple follicles and eggs for assisted reproductive technologies like IVF.
  • GnRH antagonist: A medication used in fertility treatments to prevent premature ovulation by blocking the effects of gonadotropin-releasing hormone (GnRH).
  • Ovarian Hyperstimulation Syndrome (OHSS): A potential complication of fertility treatments where the ovaries become swollen and painful due to excessive stimulation.
  • In Vitro Fertilization (IVF): A fertility treatment where eggs are retrieved from the ovaries and fertilized with sperm in a laboratory, with resulting embryos later transferred to the uterus.
  • Follicle: A fluid-filled sac in the ovary that contains a developing egg.
  • Oocyte: An immature egg cell in the ovary.
  • Embryo cryopreservation: The process of freezing and storing embryos for future use in fertility treatments.
  • Polycystic Ovary Syndrome (PCOS): A hormonal disorder that can affect fertility, characterized by irregular menstrual cycles and multiple small cysts on the ovaries.
  • Poor ovarian response: A condition where a woman's ovaries do not produce an adequate number of follicles in response to ovarian stimulation during fertility treatments.

References

  1. https://clinicaltrials.gov/study/NCT02215135
  2. https://clinicaltrials.gov/study/NCT02254928
  3. https://clinicaltrials.gov/study/NCT02490150
  4. https://clinicaltrials.gov/study/NCT01633580
  5. https://clinicaltrials.gov/study/NCT03816670
  6. https://clinicaltrials.gov/study/NCT04482751
  7. https://clinicaltrials.gov/study/NCT01408615
  8. https://clinicaltrials.gov/study/NCT02402192
  9. https://clinicaltrials.gov/study/NCT03555942
  10. https://clinicaltrials.gov/study/NCT01709331